Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) have earned a consensus rating of “Buy” from the twenty-five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $181.95.
A number of analysts recently issued reports on the company. Wells Fargo set a $182.00 target price on Jazz Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, May 15th. BidaskClub raised Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. ValuEngine raised Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. B. Riley upped their target price on Jazz Pharmaceuticals from $206.00 to $211.00 and gave the company a “buy” rating in a research report on Thursday, May 10th. Finally, Mizuho reissued a “hold” rating and issued a $150.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 9th.
Shares of Jazz Pharmaceuticals traded up $2.50, hitting $167.51, on Tuesday, MarketBeat Ratings reports. 477,750 shares of the company’s stock were exchanged, compared to its average volume of 544,817. The stock has a market cap of $10.05 billion, a P/E ratio of 17.52, a P/E/G ratio of 0.86 and a beta of 0.97. Jazz Pharmaceuticals has a 1-year low of $128.58 and a 1-year high of $168.48. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.88 and a current ratio of 3.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.73 by ($0.15). The firm had revenue of $436.40 million during the quarter, compared to analyst estimates of $440.91 million. Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. equities research analysts predict that Jazz Pharmaceuticals will post 11.65 EPS for the current year.
In other Jazz Pharmaceuticals news, SVP Karen J. Wilson sold 3,899 shares of the stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $155.00, for a total transaction of $604,345.00. Following the completion of the sale, the senior vice president now directly owns 19,517 shares of the company’s stock, valued at approximately $3,025,135. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paul Treacy sold 877 shares of the stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $139.62, for a total value of $122,446.74. The disclosure for this sale can be found here. Insiders have sold a total of 20,837 shares of company stock valued at $3,200,686 over the last ninety days. 4.30% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of JAZZ. Boston Partners purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $161,470,000. Compagnie Lombard Odier SCmA purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $577,000. Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals by 18.4% during the 4th quarter. Bank of New York Mellon Corp now owns 1,760,547 shares of the specialty pharmaceutical company’s stock worth $237,057,000 after buying an additional 274,121 shares in the last quarter. Millennium Management LLC raised its stake in shares of Jazz Pharmaceuticals by 708.4% during the 1st quarter. Millennium Management LLC now owns 220,639 shares of the specialty pharmaceutical company’s stock worth $33,314,000 after buying an additional 193,347 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 29.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 755,623 shares of the specialty pharmaceutical company’s stock worth $101,745,000 after buying an additional 171,174 shares in the last quarter. 90.62% of the stock is owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.